Developer docs
API playgroundTry for free, no card

Search company profiles

PharmaBio

Full company profile

uuid00047up

Namestring
PharmaBio
Legal namestring
PharmaBio Corporation
Websiteurl
pharmabio.co.jp
Company typeenum
Private
Founded yearint
1978
Descriptiontext

PharmaBio Corporation (ファーマバイオ株式会社) is a privately held Japanese healthcare company founded in 1978 and headquartered in Kawasaki, Kanagawa Prefecture, with operating sites in Kawasaki (Tokyo Head Office and Kawasaki Plant) and Nagoya. The company operates as Japan's first Contract Development and Manufacturing Organization (CDMO) for regenerative medicine products, a service line launched in 2011. PharmaBio provides GCTP-compliant contract manufacturing and development services for cell and tissue-derived pharmaceuticals, alongside biological safety testing services including comprehensive pathogen genetic testing (real-time PCR covering 50+ viruses and microorganisms), sterility testing, flow cytometry, ELISA, and SARS-CoV-2 PCR testing.

The company's proprietary technology platform centers on cell sheet products. Its lead asset, PAL-222, is a human allogeneic subcutaneous adipose tissue-derived mesenchymal stem cell sheet in Phase 1/2a clinical trials for myopic chorioretinal atrophy (PAMyCA Study, initiated March 2023) and neovascular age-related macular degeneration (PRESERVE Study, initiated April 2025). The mechanism involves M2 macrophage polarization for wound healing, validated through a December 2025 publication in Scientific Reports with Kyoto University. A complementary human autologous iris pigment epithelial cell sheet is also in clinical development at Nagoya City University Hospital. In February 2026, PharmaBio obtained a Regenerative Medicine Product Manufacturing and Marketing License from Kanagawa Prefecture, enabling commercial sales of regenerative medicine products.

PharmaBio operates a dual business model: (1) professional services revenue from CDMO contracts and testing services to global pharmaceutical companies, regenerative medicine developers, and cell therapy companies, and (2) proprietary drug development with future licensing/royalty potential from PAL-222 and other pipeline assets. Go-to-market is B2B enterprise sales through direct engagement, supported by a June 2020 capital and distribution alliance with Alfresa Corporation (a subsidiary of TSE-listed Alfresa Holdings) for logistics infrastructure. The company is led by President and CEO Hitoshi Kusano with Chairman Kaoru Miyauchi and Scientific Advisor Dr. Tetsuo Nagano (former PMDA Executive Director).

Short descriptiontext

PharmaBio Corporation is Japan's first regenerative medicine CDMO, providing GCTP-compliant contract manufacturing, biological safety testing, and proprietary cell sheet drug development (PAL-222 MSC sheet) for global pharmaceutical companies and academic institutions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersTokyo, Japan
HQ citystring
Tokyo
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative medicine CDMO, contract manufacturing services, cell sheet development, stem cell therapy, biological safety testing
Industry3 codes
PRIMARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Medical Laboratories8071
Product category
Regenerative Medicine CDMO Services
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Contract Manufacturing and Development Services
TypeProfessional Services
Description

PharmaBio provides contract manufacturing and development of regenerative medicine products including cell and tissue-based products, complying with GMP/GCTP standards.

pharmabio.co.jp
2Biological Safety and Sterility Testing Services
TypeProfessional Services
Description

Various contract testing services including microbial testing of cells, comprehensive pathogen microbial gene testing, sterility testing, flow cytometry, and ELISA testing.

pharmabio.co.jp
3SARS-CoV-2 Testing Services
TypeProfessional Services
Description

COVID-19 testing services added to the company's contracted testing lineup.

pharmabio.co.jp
4Development of New Regenerative Medicine Products
TypeLicensing Royalties
Description

Proprietary drug development of regenerative medicine products including PAL-222 for myopic chorioretinal atrophy and age-related macular degeneration.

pharmabio.co.jp
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

PharmaBio provides GCTP-compliant contract development and manufacturing services (CDMO) for regenerative medicine products including cell and tissue-based pharmaceuticals. The company also develops proprietary cell sheet products (PAL-222 MSC sheet and iris pigment epithelial cell sheet) and offers contract biological safety testing services including pathogen genetic testing, sterility testing, SARS-CoV-2 testing, flow cytometry, and ELISA.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • First-in-human clinical trials successfully initiated for PAL-222 in myopic chorioretinal atrophy (PAMyCA Study) and neovascular AMD (PRESERVE Study)
+1 more record
Product overview1 text field

PharmaBio is Japan's first CDMO (Contract Development and Manufacturing Organization) for regenerative medicine products, established in 1978. The company offers a portfolio of core cell sheet products and contract services. Core products include PAL-222 (human allogeneic subcutaneous adipose tissue-derived mesenchymal stem cell sheet) for ophthalmologic conditions and iris pigment epithelial cell sheet for myopic chorioretinal atrophy. The service portfolio comprises manufacturing development contract services (GCTP-compliant), safety testing services (biological safety, virus/bacteria testing, sterility testing), and specialized testing services (comprehensive pathogen genetic testing, SARS-CoV-2 testing, flow cytometry, ELISA). The company also pursues proprietary drug discovery development leveraging accumulated manufacturing expertise.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-12-26
Description

Joint research on PAL-222 MSC sheet resulting in publication in Scientific Reports journal. Research demonstrated wound healing mechanism through M2 macrophage polarization.

2Yamaguchi University
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-04-11
Description

Clinical trial agreement for PRESERVE Study - Phase 1/2a clinical trial of PAL-222 transplantation for neovascular age-related macular degeneration resistant to existing treatments.

pharmabio.co.jp
3Rohto Pharmaceutical Co., Ltd.
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-01-09
Description

Joint research agreement with Rohto Pharmaceutical (headquartered in Osaka, President: Masafumi Sugimoto) for development of novel cell sheets.

pharmabio.co.jp
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-07-26
Description

Joint R&D agreement for human allogeneic subcutaneous adipose tissue-derived mesenchymal stem cell sheet (PAL-222) for patients with myopic chorioretinal atrophy.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-12-12
Description

Joint development of manufacturing equipment and materials for cell sheets used in ophthalmologic disease transplantation treatments.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2021-02-09
Description

Clinical trial collaboration for human autologous iris pigment epithelial cell sheet transplantation for myopic chorioretinal atrophy; continued partnership for PAMyCA Study with allogeneic MSC sheet PAL-222.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2019-07-19
Description

Agreement for cell therapy material processing including cell preparation and processing related to clinical trial products.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Service provision alliance with Cell Therapies, a leading CDMO in the Asia Pacific region for cell/tissue derived medicine, to provide development manufacturing consignment for global studies.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Lonza is the global leading CDMO with extensive cell and gene therapy manufacturing services worldwide. Comparable business model (CDMO services for cell/tissue-based therapeutics) at far greater scale; poses competitive pressure on inbound global programs that could route to PharmaBio.

TypeEmerging player
Description

Healios is a Japanese regenerative medicine company developing stem cell therapies (e.g., MultiStem) for inflammatory and ophthalmic indications. Adjacent in Japanese cell therapy R&D but more biotech than CDMO; uses contract manufacturers like PharmaBio.

TypeDirect peer
Description

MEDINET provides immune cell therapy and regenerative medicine contract manufacturing services in Japan. Comparable as a Japanese cell therapy CMO serving pharma/biotech sponsors under similar GMP/GCTP frameworks.

TypeDirect peer
Description

Cell Therapies is an Australian cell and tissue CDMO that is itself a PharmaBio service-provision alliance partner. Same business model of cell therapy contract manufacturing and development, regional anchor for Asia-Pacific studies.

TypeDirect peer
Description

J-TEC (FUJIFILM subsidiary) is Japan's leading regenerative medicine products company, commercializing autologous cell sheets and cultured cartilage under Japanese regulation. Same vertical (cell/tissue-based therapeutic products, GCTP manufacturing, Japan-based), making it the closest direct comparable to PharmaBio's CDMO and PAL-222 pipeline.

6Nikon CeLL innovation Co., Ltd.
TypeDirect peer
Description

Nikon CeLL innovation operates a Japanese cell therapy CDMO with contract cell processing and manufacturing services for regenerative medicine. Direct overlap with PharmaBio's contract manufacturing and development offering for cell and tissue-based products.

TypeBroad incumbent
Description

AGC Biologics (AGC Inc.'s CDMO arm) offers cell therapy and gene therapy contract manufacturing globally, including mammalian and microbial biologics. Comparable CDMO services for cell-based therapies at larger global scale.

TypeBroad incumbent
Description

Catalent is a global CDMO with biologics and cell therapy capabilities serving pharmaceutical developers worldwide. Operates in the same broad CDMO category for advanced therapies, competing for similar global sponsor contracts.

9Alfresa Corporation (Alfresa Holdings)
TypeOthers
Description

Alfresa Corporation (subsidiary of TSE-listed Alfresa Holdings) is PharmaBio's strategic capital alliance partner for distribution infrastructure for regenerative medicine products. Not a CDMO but a key ecosystem stakeholder enabling downstream commercialization.

TypeBroad incumbent
Description

CMIC is a leading Japanese CRO and CDMO providing drug development and manufacturing services. Overlaps with PharmaBio's contract development offering and pharmaceutical manufacturing customer base within Japan.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PharmaBio

Regenerative Medicine CDMO Servicespharmabio.co.jp

PharmaBio Corporation is Japan's first regenerative medicine CDMO, providing GCTP-compliant contract manufacturing, biological safety testing, and proprietary cell sheet drug development (PAL-222 MSC sheet) for global pharmaceutical companies and academic institutions.

What PharmaBio does

PharmaBio Corporation (ファーマバイオ株式会社) is a privately held Japanese healthcare company founded in 1978 and headquartered in Kawasaki, Kanagawa Prefecture, with operating sites in Kawasaki (Tokyo Head Office and Kawasaki Plant) and Nagoya. The company operates as Japan's first Contract Development and Manufacturing Organization (CDMO) for regenerative medicine products, a service line launched in 2011. PharmaBio provides GCTP-compliant contract manufacturing and development services for cell and tissue-derived pharmaceuticals, alongside biological safety testing services including comprehensive pathogen genetic testing (real-time PCR covering 50+ viruses and microorganisms), sterility testing, flow cytometry, ELISA, and SARS-CoV-2 PCR testing.

The company's proprietary technology platform centers on cell sheet products. Its lead asset, PAL-222, is a human allogeneic subcutaneous adipose tissue-derived mesenchymal stem cell sheet in Phase 1/2a clinical trials for myopic chorioretinal atrophy (PAMyCA Study, initiated March 2023) and neovascular age-related macular degeneration (PRESERVE Study, initiated April 2025). The mechanism involves M2 macrophage polarization for wound healing, validated through a December 2025 publication in Scientific Reports with Kyoto University. A complementary human autologous iris pigment epithelial cell sheet is also in clinical development at Nagoya City University Hospital. In February 2026, PharmaBio obtained a Regenerative Medicine Product Manufacturing and Marketing License from Kanagawa Prefecture, enabling commercial sales of regenerative medicine products.

PharmaBio operates a dual business model: (1) professional services revenue from CDMO contracts and testing services to global pharmaceutical companies, regenerative medicine developers, and cell therapy companies, and (2) proprietary drug development with future licensing/royalty potential from PAL-222 and other pipeline assets. Go-to-market is B2B enterprise sales through direct engagement, supported by a June 2020 capital and distribution alliance with Alfresa Corporation (a subsidiary of TSE-listed Alfresa Holdings) for logistics infrastructure. The company is led by President and CEO Hitoshi Kusano with Chairman Kaoru Miyauchi and Scientific Advisor Dr. Tetsuo Nagano (former PMDA Executive Director).

PharmaBio firmographics

Firmographics
Name
PharmaBio
Legal name
PharmaBio Corporation
Website
https://pharmabio.co.jp
Company type
Private
Founded year
1978
Operating status
Operating
Headcount range
1–10 employees
Short description
PharmaBio Corporation is Japan's first regenerative medicine CDMO, providing GCTP-compliant contract manufacturing, biological safety testing, and proprietary cell sheet drug development (PAL-222 MSC sheet) for global pharmaceutical companies and academic institutions.
Ownership category
akta.pro rank

PharmaBio industry classification

Industry
Product category
Regenerative Medicine CDMO Services
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Regenerative medicine CDMO
  • Contract manufacturing services
  • Cell sheet development
  • Stem cell therapy
  • Biological safety testing

Where PharmaBio is headquartered

Location

Headquarters

HQ city
Tokyo
HQ country
Japan
HQ region
Asia

Offices3 records

Markets served

PharmaBio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Infrastructure, Operations, Supply Chain

Revenue model

  1. Contract Manufacturing and Development Services: PharmaBio provides contract manufacturing and development of regenerative medicine products including cell and tissue-based products, complying with GMP/GCTP standards.
  2. Biological Safety and Sterility Testing Services: Various contract testing services including microbial testing of cells, comprehensive pathogen microbial gene testing, sterility testing, flow cytometry, and ELISA testing.
  3. SARS-CoV-2 Testing Services: COVID-19 testing services added to the company's contracted testing lineup.
  4. Development of New Regenerative Medicine Products: Proprietary drug development of regenerative medicine products including PAL-222 for myopic chorioretinal atrophy and age-related macular degeneration.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

PharmaBio product offering

Product offering

Core offering

PharmaBio provides GCTP-compliant contract development and manufacturing services (CDMO) for regenerative medicine products including cell and tissue-based pharmaceuticals. The company also develops proprietary cell sheet products (PAL-222 MSC sheet and iris pigment epithelial cell sheet) and offers contract biological safety testing services including pathogen genetic testing, sterility testing, SARS-CoV-2 testing, flow cytometry, and ELISA.

Product overview

PharmaBio is Japan's first CDMO (Contract Development and Manufacturing Organization) for regenerative medicine products, established in 1978. The company offers a portfolio of core cell sheet products and contract services. Core products include PAL-222 (human allogeneic subcutaneous adipose tissue-derived mesenchymal stem cell sheet) for ophthalmologic conditions and iris pigment epithelial cell sheet for myopic chorioretinal atrophy. The service portfolio comprises manufacturing development contract services (GCTP-compliant), safety testing services (biological safety, virus/bacteria testing, sterility testing), and specialized testing services (comprehensive pathogen genetic testing, SARS-CoV-2 testing, flow cytometry, ELISA). The company also pursues proprietary drug discovery development leveraging accumulated manufacturing expertise.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • First-in-human clinical trials successfully initiated for PAL-222 in myopic chorioretinal atrophy (PAMyCA Study) and neovascular AMD (PRESERVE Study)
  • +1 more outcomes

Companies that use PharmaBio

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

PharmaBio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

PharmaBio partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered major and minor.

  • Kyoto UniversitymajorStrategic or Co-development Partner · 26 December 2025Joint research on PAL-222 MSC sheet resulting in publication in Scientific Reports journal. Research demonstrated wound healing mechanism through M2 macrophage polarization.
  • Yamaguchi UniversitymajorStrategic or Co-development Partner · 11 April 2025Clinical trial agreement for PRESERVE Study - Phase 1/2a clinical trial of PAL-222 transplantation for neovascular age-related macular degeneration resistant to existing treatments.
  • Rohto Pharmaceutical Co., Ltd.majorStrategic or Co-development Partner · 9 January 2024Joint research agreement with Rohto Pharmaceutical (headquartered in Osaka, President: Masafumi Sugimoto) for development of novel cell sheets.
  • Aize Healthcare CorporationmajorStrategic or Co-development Partner · 26 July 2023Joint R&D agreement for human allogeneic subcutaneous adipose tissue-derived mesenchymal stem cell sheet (PAL-222) for patients with myopic chorioretinal atrophy.
  • Nitta CorporationminorStrategic or Co-development Partner · 12 December 2022Joint development of manufacturing equipment and materials for cell sheets used in ophthalmologic disease transplantation treatments.
  • Nagoya City UniversitymajorStrategic or Co-development Partner · 9 February 2021Clinical trial collaboration for human autologous iris pigment epithelial cell sheet transplantation for myopic chorioretinal atrophy; continued partnership for PAMyCA Study with allogeneic MSC sheet PAL-222.
  • Janssen Pharmaceutical K.K.majorStrategic or Co-development Partner · 19 July 2019Agreement for cell therapy material processing including cell preparation and processing related to clinical trial products.
  • Cell Therapies Pty LtdminorStrategic or Co-development PartnerService provision alliance with Cell Therapies, a leading CDMO in the Asia Pacific region for cell/tissue derived medicine, to provide development manufacturing consignment for global studies.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

PharmaBio competitors and assessment

Company assessment

Broad incumbents

  • Lonza Group AG: Lonza is the global leading CDMO with extensive cell and gene therapy manufacturing services worldwide. Comparable business model (CDMO services for cell/tissue-based therapeutics) at far greater scale; poses competitive pressure on inbound global programs that could route to PharmaBio.
  • AGC Biologics: AGC Biologics (AGC Inc.'s CDMO arm) offers cell therapy and gene therapy contract manufacturing globally, including mammalian and microbial biologics. Comparable CDMO services for cell-based therapies at larger global scale.
  • Catalent, Inc. Catalent is a global CDMO with biologics and cell therapy capabilities serving pharmaceutical developers worldwide. Operates in the same broad CDMO category for advanced therapies, competing for similar global sponsor contracts.
  • CMIC Group Co., Ltd. CMIC is a leading Japanese CRO and CDMO providing drug development and manufacturing services. Overlaps with PharmaBio's contract development offering and pharmaceutical manufacturing customer base within Japan.

Emerging players

  • Healios K.K. Healios is a Japanese regenerative medicine company developing stem cell therapies (e.g., MultiStem) for inflammatory and ophthalmic indications. Adjacent in Japanese cell therapy R&D but more biotech than CDMO; uses contract manufacturers like PharmaBio.

Direct peers

  • MEDINET Co., Ltd. MEDINET provides immune cell therapy and regenerative medicine contract manufacturing services in Japan. Comparable as a Japanese cell therapy CMO serving pharma/biotech sponsors under similar GMP/GCTP frameworks.
  • Cell Therapies Pty Ltd: Cell Therapies is an Australian cell and tissue CDMO that is itself a PharmaBio service-provision alliance partner. Same business model of cell therapy contract manufacturing and development, regional anchor for Asia-Pacific studies.
  • Japan Tissue Engineering Co., Ltd. (J-TEC): J-TEC (FUJIFILM subsidiary) is Japan's leading regenerative medicine products company, commercializing autologous cell sheets and cultured cartilage under Japanese regulation. Same vertical (cell/tissue-based therapeutic products, GCTP manufacturing, Japan-based), making it the closest direct comparable to PharmaBio's CDMO and PAL-222 pipeline.
  • Nikon CeLL innovation Co., Ltd. Nikon CeLL innovation operates a Japanese cell therapy CDMO with contract cell processing and manufacturing services for regenerative medicine. Direct overlap with PharmaBio's contract manufacturing and development offering for cell and tissue-based products.

Others

  • Alfresa Corporation (Alfresa Holdings): Alfresa Corporation (subsidiary of TSE-listed Alfresa Holdings) is PharmaBio's strategic capital alliance partner for distribution infrastructure for regenerative medicine products. Not a CDMO but a key ecosystem stakeholder enabling downstream commercialization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

PharmaBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PharmaBio leadership team

Management profile

Number of profiles

Profiles6 records

PharmaBio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PharmaBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PharmaBio

What does PharmaBio do?

PharmaBio provides GCTP-compliant contract development and manufacturing services (CDMO) for regenerative medicine products including cell and tissue-based pharmaceuticals. The company also develops proprietary cell sheet products (PAL-222 MSC sheet and iris pigment epithelial cell sheet) and offers contract biological safety testing services including pathogen genetic testing, sterility testing, SARS-CoV-2 testing, flow cytometry, and ELISA.

Is PharmaBio a public or private company?

PharmaBio is a private company. It is classified as venture growth investor backed and is currently operating.

When was PharmaBio founded?

PharmaBio was founded in 1978. It employs 1 to 10 people.

Where is PharmaBio based?

PharmaBio is headquartered in Tokyo, Japan, in the Asia region.

How does PharmaBio make money?

Four revenue lines are on record. Contract Manufacturing and Development Services are the primary driver. The others are biological Safety and Sterility Testing Services, SARS-CoV-2 Testing Services and development of New Regenerative Medicine Products.

Who are PharmaBio's main competitors?

Broad incumbents on record are Lonza Group AG, AGC Biologics, Catalent, Inc. and CMIC Group Co., Ltd.. Healios K.K. is listed as an emerging player. Direct peers are MEDINET Co., Ltd., Cell Therapies Pty Ltd, Japan Tissue Engineering Co., Ltd. (J-TEC) and Nikon CeLL innovation Co., Ltd.. Alfresa Corporation (Alfresa Holdings) is listed as an others.

Does PharmaBio have an API?

No public API is recorded for PharmaBio.

What industry is PharmaBio in?

PharmaBio's product category is Regenerative Medicine CDMO Services. Its primary akta.pro industry code is HLAGABAD, Cell Therapy CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales